Allergy Therapeutics plc has received a public dealing disclosure from SkyGem Acquisition Limited, the offeror. The disclosure includes information about the positions and short positions held by SkyGem Acquisition Limited in Allergy Therapeutics plc. As of October 13, 2023, SkyGem Acquisition Limited owns and/or controls 2,850,296,476 ordinary shares of Allergy Therapeutics, representing 59.96% of the total shares. There are no cash-settled derivatives or stock-settled derivatives held by SkyGem Acquisition Limited.

The disclosure also states that there have been no purchases or sales of relevant securities by SkyGem Acquisition Limited. Additionally, there are no cash-settled derivative transactions or stock-settled derivative transactions. However, SkyGem Acquisition Limited has received shares pursuant to an equity subscription and an open offer. They received 2,228,004,131 shares at a price of 1 pence per share through the equity subscription, and 448,552,308 shares at a price of 1 pence per share through the open offer.

The disclosure does not mention any indemnity or option arrangements, agreements, or understandings related to relevant securities.